Table 3 Statistical analyses of correlation between HER2 gene copy number status and clinical data in terms of response rate (RR)

From: HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

RR

All patients

Responders

Non-responders

P -value

N =158

N =56

N =102

 

HER2- all-A vs others (HER2- non A and HER2 -minor-A)

6

2 (33%)

4 (67%)

 
   

1.0000

152

54 (35%)

98 (65%)

 

HER2- FISH+ vs HER2- FISH−

104

47 (45%)

57 (55%)

 
   

0.0004

54

9 (17%)

45 (83%)

 

HER2 -all-A vs HER2 -FISH− vs HER2 -FISH+*

6

2 (33%)

4 (67%)

 

54

9 (17%)

45 (83%)

0.0006

98

45 (46%)

53 (54%)

 
  1. Abbreviations: FISH=fluorescent in situ hybridization; HER2-all-A=HER2 gene amplification in all the sample (R:HER2/CEP17⩾2 in ⩾90% of cells); HER2-FISH+=HER2 gene copy number gain (CNG: presence of ⩾4 copies of the HER2 gene in ⩾40% of the cells) and HER2-A (HER2 gene amplification as R:HER2/CEP17⩾2 in ⩾10% of cells); HER2-FISH−=absence of CNG and absence of HER2 amplification; HER2-minor-A=HER2 gene amplification in a minor population (10–60% of cells); HER2-non-A=absence of HER2 gene amplification. Significant P-values are in bold. P-values for RR were calculated using Chi-square test.
Back to article page